Co-crystals of Formula I compounds and their pharmaceutical compositions are novel therapeutics for the treatment of diseases, such as human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and cancer. The co-crystal are more stable to oxidation and aqueous degradation, have a better pharmacokinetic profile and superior biological activity than the corresponding tosylate salt form of Formula I compound.
Formula I化合物的共晶体及其药物组合物是治疗疾病的新型治疗药物,例如人类免疫缺陷病毒(HIV)感染、乙型肝炎病毒(HBV)感染、丙型肝炎病毒(HCV)感染和癌症。这些共晶体比Formula I化合物对应的
对甲苯磺酸盐形式更稳定,对氧化和
水解更稳定,具有更好的药代动力学特性和优越的
生物活性。